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Association of Obesity With Severity of Heart Failure Exacerbation:
A Population-Based Study
Atsushi Hirayama, MD, MPH; Tadahiro Goto, MD, MPH; Yuichi J. Shimada, MD, MPH; Mohammad Kamal Faridi, MPH; Carlos A. Camargo Jr
MD, DrPH; Kohei Hasegawa, MD, MPH
Background-—Obesity and heart failure (HF) are important public health problems in the United States. Although studies have
reported the association between obesity and higher chronic morbidity of HF, little is known about the relations of obesity with
severity of HF exacerbation and in-hospital mortality; therefore, we aimed to investigate the associations of obesity with severity of
HF exacerbation and in-hospital mortality.
Methods and Results-—This retrospective cohort study of adults hospitalized for HF exacerbation used population-based data sets
(the State Inpatient Databases) of 7 US states from 2012 to 2013. The outcomes were acute severity measures—use of positive
pressure ventilation and hospital length of stay—and in-hospital mortality. We determined the associations between obesity and
these outcomes, including adjustment for sociodemographic factors and comorbidities. We identiﬁed 219 465 patients
hospitalized for HF exacerbation. Of those, 37 539 (17.1%) were obese. Obese patients had a signiﬁcantly higher risk of positive
pressure ventilation use compared with nonobese patients (13.6% versus 8.8%), with a corresponding adjusted odds ratio of 1.61
(95% conﬁdence interval, 1.55–1.68; P<0.001). Likewise, obese patients were more likely to have hospital length of stay of
≥4 days compared with nonobese patients (62.5% versus 56.7%), with an adjusted odds ratio of 1.40 (95% conﬁdence interval,
1.37–1.44; P<0.001). In contrast, obese patients had signiﬁcantly lower in-hospital mortality compared with nonobese patients
(1.7% versus 3.3%), with an adjusted odds ratio of 0.87 (95% conﬁdence interval, 0.80–0.95; P=0.002).
Conclusions-—Based on large population-based data sets of patients with HF exacerbation, obesity was associated with higher
acute severity measures but lower in-hospital mortality. ( J Am Heart Assoc. 2018;7:e008243. DOI: 10.1161/JAHA.117.
008243.)
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H eart failure (HF) affects approximately 2% (6.5 million)of Americans and is responsible for 1 million hospital-
izations each year.1 In parallel, the United States is in the
midst of obesity epidemic with 35% (105 million) of adults
obese.2 Furthermore, the societal burdens of HF and obesity
are rising, with estimates of >8 million Americans having HF1
and 125 million being obese by 2030.3
Emerging evidence indicates a link between obesity and
chronic morbidity with HF. Obese patients with HF have a
greater risk of chronic comorbidities of HF (eg, arrhythmia,
coronary heart disease)4 and increased frequency of HF
exacerbation.5 In contrast to associations seen in the general
population, obesity is associated to a certain degree with
lower long-term mortality compared with healthy weight
among patients with HF.6,7 Despite the public health and
clinical importance of HF exacerbation, little is known about
the relationship of obesity with severity of HF exacerbation
and in-hospital mortality.
To address this knowledge gap, we used population-based
data to investigate the association of obesity with acute
severity measures and in-hospital mortality among patients
hospitalized for HF exacerbation. We considered use of
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positive pressure ventilation (PPV) and hospital length of stay
(LOS) as the measures of severity of hospitalization, based on
previous literature.8–12
Methods
Study Design and Setting
We conducted a retrospective cohort study using large,
population-based, multi-payer data from the Healthcare Cost
and Utilization Project (HCUP) State Inpatient Databases
(SID) of 7 geographically dispersed US states (Arkansas,
Florida, Iowa, Nebraska, New York, Utah, and Washington)
between 2012 and 2013. The HCUP is a family of
healthcare databases developed through a federal, state,
and industry partnership and sponsored by the US Agency
for Healthcare Research and Quality. The data, analytic
methods, and study materials have been made available to
other researchers for purposes of reproducing the results or
replicating the procedure. HCUP’s Nationwide and State-
Speciﬁc Databases are available for purchase from the
online HCUP distributor.13 HCUP is the largest collection of
longitudinal hospital care data in the United States, with all-
payer, encounter-level information. The SID captures all
hospitalizations, regardless of source, from short-term, acute
care, nonfederal, general, and other specialty hospitals.
Additional details of the HCUP SID can be found else-
where.13 These 7 states were selected for their geographic
distribution and high data quality and because their data
included unique encrypted patient identiﬁers that enable
longitudinal follow-up of speciﬁc individuals across years.
The institutional review board of Massachusetts General
Hospital approved this study, and the requirement for
informed consent was waived.
Study Population
We identiﬁed all hospitalized adult patients (aged ≥18 years)
with a principal discharge diagnosis of HF exacerbation, as
deﬁned by the International Classiﬁcation of Diseases, Ninth
Revision, Clinical Modiﬁcation (ICD-9-CM) diagnosis codes of
402.01, 402.11, 402.91, 404.01, 404.03, 404.11, 404.13,
404.91, 404.93, and 428.0.14,15 These ICD-9-CM codes have
high speciﬁcity and positive predictive value to identify HF
(both ≥90%).16 We included only the ﬁrst nonelective hospi-
talization for HF exacerbation for each patient during the
study period. We excluded patients who left the hospital
against medical advice and those who were underweight
(deﬁned by ICD-9-CM diagnosis codes of 783.2, 783.21,
783.22, and v85.0).17
Measurements
The SID contains information on the patient characteristics,
including demographics (age, sex, and race/ethnicity), pri-
mary insurance type (payer), estimated household income,
patient residence, ICD-9-CM diagnosis and procedure codes,
patient comorbidities, hospital LOS, in-hospital death, and
disposition. Quartile classiﬁcations of estimated median
household income of residents in the patient’s ZIP code were
examined. Patient residence status was deﬁned according to
the National Center for Health Statistics.18
Primary Exposure
The primary exposure was obesity (body mass index ≥30) at
the index hospitalization for HF exacerbation, as deﬁned by
the ICD-9-CM diagnosis codes of 278.00, 278.01, V85.3x, and
V85.4x in any diagnosis ﬁeld.9 These ICD-9-CM codes have
high speciﬁcity and positive predictive value to identify
obesity (both >90%).16
Outcome Measures
The primary outcomes were acute severity measures—
namely, use of PPV (including both noninvasive and invasive
PPV) during hospitalization and hospital LOS—and in-hospital
mortality. The use of noninvasive PPV was identiﬁed by ICD-9-
CM procedure code 93.90, and the use of invasive PPV was
identiﬁed by codes 96.04 and 96.70 to 96.72.9,19
Statistical Analyses
First, we compared the patient characteristics between the
obesity and nonobesity groups using the Wilcoxon rank sum
test or the v2 test, as appropriate. Second, to examine the
associations of obesity with the acute severity measures and
Clinical Perspective
What Is New?
• In the analysis of population-based data sets with 219 465
patients hospitalized for heart failure exacerbation, obesity
was associated with acute severity of heart failure (ie, higher
use of positive pressure ventilation and longer hospital
length of stay) but lower in-hospital mortality compared with
nonobesity.
What Are the Clinical Implications?
• Our study suggested that obesity is an important clinical
factor in both long-term and acute care of heart failure.
• Our observations should encourage further research into
the mechanisms linking obesity to severity of heart failure
exacerbation and mortality.
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in-hospital mortality, we constructed unadjusted and adjusted
logistic regression models with generalized estimating equa-
tions accounting for clustering of patients within hospitals. In
the multivariable models, we adjusted for age, sex, race/
ethnicity, primary insurance, quartiles for median household
income, residential status, 27 comorbidities (Elixhauser
comorbidity measures20 except for congestive HF and
obesity) and arrhythmia, and hospital state. In this primary
analysis, the hospital LOS was modeled as a binomial
response (≤3 versus ≥4 days) based on the median LOS in
the study population.
To examine the robustness of our inference, we per-
formed a series of sensitivity analyses. First, to examine the
association between obesity and hospital LOS as a count
variable, we constructed negative binomial regression mod-
els with generalized estimating equations. Second, we
repeated the analyses with stratiﬁcation by age (19–39,
40–64, and ≥65 years), sex (men, women), and diabetes
mellitus status (deﬁned by using Elixhauser comorbidity
measures). In addition, we repeated the analyses with
stratiﬁcation by obstructive sleep apnea status because
obstructive sleep apnea is associated with obesity.21 Last,
we used stabilized inverse probability weighting (IPW) to
estimate the causal relation of obesity with the outcomes in
this observational study. Weighting participants by the
inverse probability of having an exposure (obesity) creates
a synthetic sample in which the exposure is independent
from the measured baseline covariates—that is, in the
synthetic sample, obese and nonobese individuals are
exchangeable.22 Although conventional IPW enables us to
obtain estimates of average effects of the exposure on
outcomes, participants with very low or high probability
increase the variability of the estimated effects. Instead,
stabilized IPW addresses this issue and directly estimates
both the main effect and its variance from conventional
regression models. All analyses used STATA 14.0 (Stata-
Corp). All P values were 2-tailed, with P<0.05 considered
statistically signiﬁcant.
Table 1. Characteristics of Patients Hospitalized for HF
Exacerbation by Obesity Status
Characteristics
Obesity
n=37 539
(17.1%)
Nonobesity
n=181 926
(82.9%) P Value
Age, y, median (IQR) 67 (57–76) 79 (68–87) <0.001
Women 19 308 (51.4) 89 634 (49.3) <0.001
Race/ethnicity <0.001
Non-Hispanic white 23 223 (63.3) 121 685 (70.0)
Non-Hispanic black 8148 (22.2) 24 846 (14.3)
Hispanic 3641 (9.9) 17 052 (9.8)
Asian or Pacific
Islander
248 (0.7) 2737 (1.6)
Native American 132 (0.4) 487 (0.3)
Others 1318 (3.6) 7070 (4.1)
Primary health
insurance
<0.001
Medicare 24 678 (65.7) 146 520 (80.5)
Medicaid 4460 (11.9) 11 580 (6.4)
Private 5.702 (15.2) 15 936 (8.8)
No insurance 1625 (4.3) 4143 (2.3)
No charge 318 (0.9) 704 (0.4)
Others 756 (2.0) 3037 (1.7)
Quartiles for median
household income
<0.001
1 (lowest) 12 679 (34.7) 51 426 (29.0)
2 9752 (26.7) 46 574 (26.3)
3 8428 (23.1) 43 175 (24.4)
4 (highest) 5654 (15.5) 36 092 (20.4)
Patient residence <0.001
Metropolitan 25 825 (84.0) 155 837 (85.8)
Nonmetropolitan 4913 (16.0) 32 558 (17.3)
Selected comorbidities*
Cardiac arrhythmia 19 200 (51.2) 107 444 (59.1) <0.001
Chronic pulmonary
disease
21 250 (56.6) 82 870 (45.6) <0.001
Diabetes mellitus 23 769 (63.3) 70 307 (38.9) <0.001
Depression 4897 (13.1) 17 609 (9.7) <0.001
Hypertension 32 018 (85.3) 143 090 (78.7) <0.001
Peripheral vascular
disease
3879 (10.3) 21 247 (11.7) <0.001
Renal failure 15 444 (41.1) 73 202 (40.2) <0.001
Valvular disease 8363 (22.3) 58 410 (32.1) <0.001
Hospital state <0.001
Arkansas 1816 (4.8) 10 076 (5.5)
Florida 18 061 (48.1) 72 047 (39.6)
Continued
Table 1. Continued
Characteristics
Obesity
n=37 539
(17.1%)
Nonobesity
n=181 926
(82.9%) P Value
Iowa 1520 (4.1) 8124 (4.5)
Nebraska 340 (0.9) 4965 (2.7)
New York 11 700 (31.2) 65 596 (36.1)
Utah 316 (0.8) 4428 (2.4)
Washington 3786 (10.1) 16 690 (9.2)
Data are shown as n (%) unless otherwise speciﬁed. HF indicates heart failure; IQR,
interquartile range.
*Selected from Elixhauser comorbidity measures.
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Results
Patient Characteristics
We identiﬁed 223 380 patients with nonelective hospitaliza-
tion for HF exacerbation in the 7 states between January 2012
and December 2013. Of these, we excluded 2755 patients
who left the hospital against medical advice and 1160 who
were diagnosed as underweight. A total of 219 465 patients
were eligible for the analysis. The median age was 77 years
(interquartile range: 66–86 years), 49.6% were female, and
17.1% were obese. Patient characteristics differed between
the obese and nonobese groups (Table 1). For example, obese
patients were younger and were more likely to be non-
Hispanic black and to have chronic pulmonary disease,
diabetes mellitus, depression, and hypertension compared
with nonobese patients (all P<0.001).
Association of Obesity With Acute Severity
Measures and In-Hospital Mortality
Figure summarizes the unadjusted and adjusted associations
of obesity with each outcome. Obese patients had a higher
risk of PPV use compared with nonobese patients (13.6%
versus 8.8%) in both unadjusted (odds ratio [OR]: 1.72) and
adjusted (adjusted OR: 1.61) models. Likewise, obese
patients had a signiﬁcantly higher risk of noninvasive PPV
use (adjusted OR: 1.75) and nonsigniﬁcantly higher risk of
invasive PPV use (adjusted OR: 1.08). Similarly, obese
patients were more likely to have hospital LOS ≥4 days
(62.5% versus 56.7%), with a corresponding adjusted OR of
1.40. In the analysis modeling hospital LOS as a count
variable, obese patients also had signiﬁcantly longer hospital
LOS, corresponding to an 11% increase in the adjusted model
(95% conﬁdence interval, 10–13% increase; P<0.001;
Table S1). In the sensitivity analyses stratiﬁed by age
(Table 2), sex (Table 3), obstructive sleep apnea status
(Table 4), and diabetes mellitus status (Table S2) and in the
analysis with stabilized IPW (Table S3), all of these associa-
tions were consistent.
In contrast, obesity was associated with signiﬁcantly lower
in-hospital mortality compared with nonobesity (1.7% versus
3.3%; unadjusted OR: 0.55). The magnitude of the association
attenuated after adjusting for patient sociodemographic
factors and comorbidities (adjusted OR: 0.87). Likewise, in
the sensitivity analyses stratiﬁed by age (Table 2), sex
(Table 3), obstructive sleep apnea status (Table 4), and
Figure. Unadjusted and adjusted associations of obesity with acute severity measures and in-hospital mortality in patients hospitalized for
heart failure exacerbation. Obesity was associated with a higher risk of positive pressure ventilation (PPV) use and longer hospital length of stay
(LOS) compared with nonobesity. In contrast, obesity was associated with lower in-hospital mortality compared with nonobesity. CI indicates
conﬁdence interval; IPPV, invasive positive pressure ventilation; NIPPV, noninvasive positive pressure ventilation; OR, odds ratio.
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diabetes mellitus status and in the analysis with stabilized IPW
(Table S3), obese patients tended to have lower in-hospital
mortality.
Discussion
In this population-based study of 219 465 patients hospital-
ized for HF exacerbation, we found that obesity was
associated with a higher risk of PPV use and longer hospital
LOS and that these signiﬁcant associations persisted after
adjustment for potential confounders. In contrast, obesity was
associated with lower in-hospital mortality. These ﬁndings
were consistent across different statistical assumptions,
including the stabilized IPW method. To the best of our
knowledge, this study is the ﬁrst that has comprehensively
investigated the relation of obesity with acute severity in
patients with HF exacerbation. The ﬁndings have both clinical
and research importance.
Although prior epidemiologic studies have reported asso-
ciations between obesity and higher chronic HF severity (eg,
incident coronary heart disease, frequent HF exacerbation),15
surprisingly little is known about the impact of obesity on the
severity of HF exacerbation. The underlying mechanisms of
our new ﬁndings—the observed link between obesity and
acute HF exacerbation—are likely multifactorial. Although
obesity-related comorbidities (eg, the higher prevalence of
chronic pulmonary diseases in obese patients) played a role,
the associations remained signiﬁcant after adjustment for
these comorbidities. Alternatively, obesity-related physiolog-
ical and biological changes—for example, left ventricular
hypertrophy and diastolic dysfunction,23 activation of the
renin–angiotensin–aldosterone axis,24 increased sympathetic
tone,25 hyperleptinemia,26 and systemic inﬂammation27—
may have contributed to the severity of HF exacerbation. In
addition, obesity and acute severity (higher PPV use and
longer hospital LOS) was observed in other population (ie,
patients hospitalized for chronic obstructive pulmonary
disease).9 Our study builds on prior epidemiologic and
mechanistic studies of the obesity–HF link and extends them
by demonstrating the association of obesity with acute
severity measures in this large population-based sample of HF
exacerbation.
Table 2. Unadjusted and Adjusted Associations of Obesity With Acute Severity Measures and In-Hospital Mortality of HF
Exacerbation by Age Category
Outcomes and Age Groups
Obesity,
% (95% CI)
Nonobesity,
% (95% CI)
Unadjusted
OR (95% CI) P Value
Adjusted OR*
(95% CI) P Value
Aged 18–39 y (n=3784)
PPV use 12.3 (10.7–14.1) 6.5 (5.6–7.6) 2.21 (1.74–2.80) <0.001 3.24 (2.42–4.35) <0.001
NIPPV 10.2 (8.0–11.8) 3.4 (2.7–4.2) 3.29 (2.46–4.41) <0.001 4.05 (2.86–5.71) <0.001
IPPV 2.6 (1.8–3.5) 3.4 (2.7–4.2) 0.90 (0.60–1.35) 0.60 1.83 (1.10–3.03) 0.02
Hospital LOS ≥4 d 51.7 (49.1–54.3) 51.9 (49.8–53.9) 1.03 (0.91–1.18) 0.614 1.17 (0.99–1.36) 0.051
In-hospital mortality 1.0 (0.6–1.6) 1.5 (1.0–1.9) 0.73 (0.39–1.37) 0.32 † †
Aged 40–64 y (n=46 696)
PPV use 13.7 (13.2–14.3) 9.1 (8.7–9.4) 1.73 (1.62–1.85) <0.001 1.72 (1.60–1.84) <0.001
NIPPV 11.7 (11.5–12.2) 6.3 (6.0–6.6) 2.16 (2.00–2.33) <0.001 1.97 (1.82–2.13) <0.001
IPPV 2.6 (2.3–2.9) 3.2 (3.0–3.4) 0.81 (0.71–0.92) 0.001 0.98 (0.85–1.12) 0.73
Hospital LOS ≥4 d 59.8 (59.0–60.6) 52.8 (52.3–53.4) 1.34 (1.29–1.39) <0.001 1.41 (1.34–1.47) <0.001
In-hospital mortality 1.1 (1.0–1.3) 1.5 (1.4–1.7) 0.79 (0.66–0.97) 0.01 0.97 (0.80–1.18) 0.77
Aged ≥65 y (n=168 985)
PPV use 13.6 (13.1–14.1) 8.8 (8.7–9.0) 1.72 (1.64–1.80) <0.001 1.59 (1.51–1.67) <0.001
NIPPV 11.8 (11.4–12.3) 7.2 (7.1–7.3) 1.85 (1.75–1.94) <0.001 1.65 (1.56–1.73) <0.001
IPPV 2.3 (2.1–2.5) 1.9 (1.8–2.0) 1.20 (1.09–1.33) <0.001 1.24 (1.12–1.38) <0.001
Hospital LOS ≥4 d 64.9 (64.3–65.6) 57.6 (57.3–57.9) 1.37 (1.33–1.42) <0.001 1.35 (1.30–1.39) <0.001
In-hospital mortality 2.1 (2.0–2.3) 3.7 (3.6–3.8) 0.60 (0.55–0.66) <0.001 0.69 (0.63–0.77) <0.001
CI indicates conﬁdence interval; HF, heart failure; IPPV, invasive positive pressure ventilation; LOS, length of stay; NIPPV, noninvasive positive pressure ventilation; OR, odds ratio; PPV,
positive pressure ventilation.
*Logistic regression model with generalized estimating equations to account for patient clustering within hospitals, adjusting for sex, race/ethnicity, primary insurance, quartiles for
household income, residential status, 28 comorbidity measures, and hospital state.
†Not computed because of the small number of outcome events (n=48).
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The paradoxical relation of obesity with in-hospital mortal-
ity is novel but consistent with prior studies showing that
obese patients with HF have favorable long-term survival
outcomes compared with nonobese patients with HF. A
cohort study of 6142 patients, for example, reported that
obese patients with HF had signiﬁcantly lower 30-day and
1-year mortality rates.28 In addition, within the limited
literature, few studies also investigated the relation of obesity
with in-hospital mortality. In the analysis of 108 927 hospi-
talizations for HF exacerbation in the United States, higher
body mass index was associated with lower in-hospital
mortality.29 The reasons for the association between obesity
Table 3. Unadjusted and Adjusted Associations of Obesity With Acute Severity Measures and In-Hospital Mortality of HF
Exacerbation by Sex
Outcomes and Sex Groups
Obesity,
% (95% CI)
Nonobesity,
% (95% CI)
Unadjusted
OR (95% CI) P Value
Adjusted
OR* (95% CI) P Value
Men (n=110 523)
PPV use 13.4 (12.9–13.9) 8.5 (8.3–8.7) 1.78 (1.68–1.87) <0.001 1.72 (1.63–1.83) <0.001
NIPPV 11.6 (11.1–12.0) 6.4 (6.3–6.6) 2.04 (1.92–2.16) <0.001 1.93 (1.81–2.05) <0.001
IPPV 2.5 (2.2–2.7) 2.4 (2.3–2.5) 1.03 (0.93–1.15) 0.55 1.06 (0.95–1.20) 0.29
Hospital LOS ≥4 d 59.9 (59.2–60.7) 55.4 (55.1–55.7) 1.21 (1.17–1.25) <0.001 1.36 (1.31–1.42) <0.001
In-hospital mortality 1.7 (1.5–1.9) 3.3 (3.2–3.4) 0.53 (0.47–0.60) <0.001 0.88 (0.77–0.99) 0.04
Women (n=108 942)
PPV use 13.7 (13.2–14.2) 9.2 (9.0–9.4) 1.64 (1.56–1.72) <0.001 1.51 (1.43–1.60) <0.001
NIPPV 11.9 (11.4–12.3) 7.6 (7.4–7.7) 1.73 (1.63–1.83) <0.001 1.61 (1.52–1.71) <0.001
IPPV 2.4 (2.2–2.6) 2.0 (1.9–2.1) 1.22 (1.09–1.36) 0.001 1.06 (0.94–1.20) 0.32
Hospital LOS ≥4 d 64.8 (64.1–65.5) 58.0 (57.7–58.4) 1.34 (1.30–1.38) <0.001 1.45 (1.39–1.50) <0.001
In-hospital mortality 1.7 (1.5–1.9) 3.2 (3.1–3.3) 0.56 (0.50–0.63) <0.001 0.86 (0.75–0.97) 0.02
CI indicates conﬁdence interval; HF, heart failure; IPPV, invasive positive pressure ventilation; LOS, length of stay; NIPPV, noninvasive positive pressure ventilation; OR, odds ratio; PPV,
positive pressure ventilation.
*Logistic regression model with generalized estimating equations to account for patient clustering within hospitals, adjusting for age, race/ethnicity, primary insurance, quartiles for
household income, residential status, 28 comorbidity measures, and hospital state.
Table 4. Unadjusted and Adjusted Associations of Obesity With Acute Severity Measures and In-Hospital Mortality of HF
Exacerbation by OSA Status
Outcomes and OSA Groups
Obesity,
% (95% CI)
Nonobesity,
% (95% CI)
Unadjusted
OR (95% CI) P Value
Adjusted
OR* (95% CI) P Value
OSA (n=20 732)
PPV use 19.5 (18.4–20.7) 13.0 (11.9–14.1) 1.48 (1.38–1.60) <0.001 1.39 (1.28–1.52) <0.001
NIPPV 16.6 (15.9–17.3) 11.3 (10.7–12.0) 1.49 (1.37–1.61) <0.001 1.36 (1.25–1.49) <0.001
IPPV 3.1 (2.8–3.4) 2.0 (1.8–2.3) 1.50 (1.25–1.81) <0.001 1.58 (1.27–1.96) <0.001
Hospital LOS ≥4 d 61.9 (61.0–62.8) 54.1 (53.0–55.1) 1.33 (1.26–1.41) <0.001 1.45 (1.36–1.56) <0.001
In-hospital mortality 2.0 (1.7–2.3) 2.7 (2.4–3.1) 0.71 (0.59–0.85) <0.001 1.00 (0.80–1.25) 0.99
Non-OSA (n=198 733)
PPV use 10.4 (9.9–11.2) 8.6 (8.3–9.0) 1.18 (1.12–1.24) <0.001 1.19 (1.12–1.26) <0.001
NIPPV 7.1 (6.7–7.4) 6.0 (5.9–6.1) 1.22 (1.15–1.30) <0.001 1.22 (1.15–1.31) <0.001
IPPV 3.4 (3.2–3.6) 3.2 (3.1–3.3) 1.10 (1.00–1.21) 0.04 1.10 (0.99–1.22) 0.07
Hospital LOS ≥4 d 62.6 (62.0–63.2) 57.0 (56.7–57.3) 1.22 (1.19–1.25) <0.001 1.35 (1.30–1.39) <0.001
In-hospital mortality 1.7 (1.6–1.9) 3.6 (3.4–3.6) 0.55 (0.50–0.60) <0.001 0.86 (0.77–0.95) 0.002
CI indicates conﬁdence interval; HR, heart failure; IPPV, invasive positive pressure ventilation; LOS, length of stay; NIPPV, noninvasive positive pressure ventilation; OSA, obstructive sleep
apnea; OR, odds ratio; PPV, positive pressure ventilation.
*Logistic regression model with generalized estimating equations to account for patient clustering within hospitals, adjusting for age, race/ethnicity, primary insurance, quartiles for
household income, residential status, 28 comorbidity measures, and hospital state.
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and lower in-hospital mortality remain to be elucidated. The
observed attenuation of the association after adjustment
indicates that the covariates in the model (eg, younger age in
obese patients) partially explain the association. Another
possible explanation is that obese patients were more likely to
have PPV therapy, and it mediated the association between
obesity and in-hospital mortality. The use of PPV has been
shown to improve clinical outcomes in patients with severe
respiratory function impairment.30 In addition, the observed
association may be attributable to biological factors, such as
lower production of circulating natriuretic peptides and
greater clearance, that potentially lead to obese patients
becoming symptomatic earlier.31 Greater metabolic reserve
from acute HF–induced catabolic state32 may also explain the
protective role of obesity. Moreover, unless they have
sarcopenic obesity, obese patients have typically increased
lean mass associated with excess body fat, and lean mass is
associated with greater cardiorespiratory ﬁtness in HF,33–35
which may also explain the protective role of obesity.
Furthermore, it is possible that obese patients were hospital-
ized with relatively lower severity compared with nonobese
patients, thereby inﬂating their denominator. Any combination
of these factors may have contributed, at least in part, to the
observed association between obesity and lower in-hospital
mortality in this population.
Potential Limitations
Our study has several potential limitations. First, although the
HCUP data are thought to be accurate and are widely used to
capture diagnoses and hospitalizations,15,36 misclassiﬁca-
tions are possible. However, the ICD-9-CM codes that are
used to identify obesity and HF have been validated14,15 and
are known to have high speciﬁcity and positive predictive
value (both >90%).16 Furthermore, the prevalence of obesity
in our cohort (17%) was comparable to the prevalence of
obesity in previous HF cohorts (15–28%).28,37–39 In addition,
assuming misclassiﬁcation occurred equally regardless of the
outcomes, the results would have biased our estimates
toward the null. Second, our data did not include the category
of obesity or detailed left ventricular function. Because
previous studies have indicated that the effect of obesity on
clinical outcome differs between morbidly obese and less
severely obese participants,40 caution should be used in
generalizing the current results. Third, as with any observa-
tional study, the causal inference of obesity with acute
severity measures and in-hospital mortality might be con-
founded by unmeasured factors (eg, etiology of HF, left
ventricular function, chronic severity, and institutional varia-
tion in resource use); however, the observed associations
between obesity and outcomes remained signiﬁcant after
accounting for patient clustering within hospitals. Fourth, the
studied data are limited by not being a random sample of the
entire nation; however, the data are racially/ethnically and
geographically diverse. The 7 states together represent
approximately 20% of the US population, thereby supporting
the generalizability of our inferences. Finally, the study
population comprised only patients hospitalized for HF
exacerbation. Consequently, our inferences might not be
generalizable to patients with less severe HF exacerbation
that does not require hospitalization. Nevertheless, our data
remain highly relevant for the 1 million patients hospitalized
for HF in the United States each year,41 a population with
high morbidity and healthcare utilization.
Conclusions
By using population-based data sets with 219 465 patients
hospitalized for HF exacerbation across 7 US states, we found
that obese patients had higher acute severity measures, such
as more use of PPV and longer hospital LOS, while also having
lower in-hospital mortality. These associations persisted
across different statistical assumptions. Our observations
should encourage further research into the mechanisms
linking obesity to severity of HF exacerbation and mortality.
Furthermore, given the obesity and HF epidemic in the United
States, our ﬁndings underscore the importance of continued
efforts to develop effective treatment strategies for obese
patients with HF exacerbation.
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Supplemental Material 
 
 
 
Table S1. Unadjusted and adjusted associations of obesity with hospital length-of-stay among patients hospitalized with heart 
failure exacerbation. 
 
Obesity 
Hospital LOS, 
median (IQR), day 
Non-obesity 
Hospital LOS, 
median (IQR), 
day  
Unadjusted % change 
in hospital LOS* 
(95%CI) P value 
Adjusted % change in 
hospital LOS* (95%CI) 
P 
value 
Overall 4 (3-7) 4 (2-6) 9% (7% to 10%) <0.001 11% (10% to 13%) <0.001 
Age group       
  18-39 years 4 (2-6) 4 (2-6) -9% (-17% to -5%) <0.001 4% (-4% to 13%) 0.31 
40-64 years 4 (3-7) 4 (2-6) 5% (3% to 7%) <0.001 11% (9% to 14%) <0.001 
≥65 years 5 (3-7) 4 (3-6) 13% (11% to 14%) <0.001 12% (10% to 14%) <0.001 
Sex       
Male 4 (3-7) 4 (2-6) 6% (4% to 8%) <0.001 10% (8% to 12%) <0.001 
Female 5 (3-7) 4 (3-6) 12% (10% to 14%) <0.001 12% (10% to 14%) <0.001 
Abbreviations: CI, confidence interval; LOS, length-of-stay 
* Unadjusted and adjusted negative binomial regression models using generalized estimating equations to account for patient 
clustering within hospitals.  
  
Table S2. Unadjusted and adjusted associations of obesity with acute severity measures and in-hospital mortality of heart failure exacerbation, 
according to diabetes mellitus status. 
Outcomes and DM groups 
Obesity  
(95%CI) 
Non-obesity  
(95%CI) 
Unadjusted OR 
 (95%CI) P value 
Adjusted OR* 
(95%CI) P value 
DM (n=94,076)       
Positive pressure ventilation use 14.5% (13.7%-15.2%) 9.3% (9.0%-9.7%) 1.69 (1.57-1.81) <0.001 1.59 (1.46-1.74) <0.001 
 NIPPV 12.4% (11.7%-13.1%) 7.7% (7.3%-8.0%) 1.85 (1.73-1.97) <0.001 1.70 (1.55-1.87) <0.001 
 IPPV 2.7% (2.4%-3.0%) 2.4% (2.2%-2.6%) 1.15 (0.84-1.27) 0.76 1.13 (0.95-1.35) 0.17 
Hospital LOS ≥4 days 63.9% (62.9%-64.9%) 56.9% (56.2%-57.5%) 1.30 (1.21-1.39) <0.001 1.38 (1.30-1.47) <0.001 
In-hospital mortality 1.6% (1.2%-2.0%) 3.0% (2.7%-3.3%) 0.61 (0.51-0.72) <0.001 0.83 (0.69-1.01) 0.06 
Non-DM (n=125,389)       
Positive pressure ventilation 
use 
12.4% (11.6-13.2%) 8.4% (8.1%-8.8%) 1.59 (1.46-1.73) <0.001 1.56 (1.46-1.74) <0.001 
 NIPPV 10.5% (9.5%-11.5%) 6.7% (6.3%-8.1%) 1.80 (1.66-1.97) <0.001 1.76 (1.57-1.98) <0.001 
 IPPV 2.2% (1.9%-2.7%) 2.1% (2.0%-2.3%) 1.03 (0.88-1.23) 0.76 0.92 (0.73-1.16) 0.48 
Hospital LOS ≥4 days 59.5% (58.2%-60.9%) 53.2% (52.7%-53.7%) 1.30 (1.21-1.38) <0.001 1.52 (1.41-1.63) <0.001 
In-hospital mortality 1.7% (1.3%-2.1%) 4.0% (3.9%-4.1%) 0.48 (0.39-0.57) <0.001 0.73 (0.58-0.92) 0.01 
Abbreviations: OR, odds ratio; CI, confidence interval; DM, diabetes mellitus; NIPPV, non-invasive positive pressure ventilation; IPPV, invasive positive 
pressure ventilation; LOS, length-of-stay. 
* Logistic regression model with generalized estimating equations to account for patient clustering within hospitals, adjusting for age, race/ethnicity, primary 
insurance, quartiles for household income, residential status, 28 comorbidity measures, and hospital state. 
 
Table S3. Associations of obesity with acute severity measures of heart failure exacerbation and in-hospital mortality using 
stabilized inverse probability weighting method. 
Outcomes 
Odds Ratio 
 (95%CI) P value 
Positive pressure ventilation 
use 
1.59 (1.50-1.69) <0.001 
 NIPPV 1.73 (1.62-1.86) <0.001 
 IPPV 1.10 (0.98-1.23) 0.11 
Hospital LOS ≥4 days 1.39 (1.33-1.45) <0.001 
In-hospital mortality 0.85 (0.74-0.97) 0.02 
Abbreviations: OR, odds ratio; CI, confidence interval; NIPPV, non-invasive positive pressure ventilation; IPPV, invasive positive 
pressure ventilation; LOS, length-of-stay. 
 
